155 related articles for article (PubMed ID: 32168360)
1. Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis.
Packeiser EM; Hewicker-Trautwein M; Thiemeyer H; Mohr A; Junginger J; Schille JT; Murua Escobar H; Nolte I
PLoS One; 2020; 15(3):e0230272. PubMed ID: 32168360
[TBL] [Abstract][Full Text] [Related]
2. RNA-seq of nine canine prostate cancer cell lines reveals diverse therapeutic target signatures.
Packeiser EM; Taher L; Kong W; Ernst M; Beck J; Hewicker-Trautwein M; Brenig B; Schütz E; Murua Escobar H; Nolte I
Cancer Cell Int; 2022 Feb; 22(1):54. PubMed ID: 35109825
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.
Allstadt SD; Rodriguez CO; Boostrom B; Rebhun RB; Skorupski KA
J Vet Intern Med; 2015 Jan; 29(1):261-7. PubMed ID: 25619518
[TBL] [Abstract][Full Text] [Related]
4. Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer.
Dhawan D; Paoloni M; Shukradas S; Choudhury DR; Craig BA; Ramos-Vara JA; Hahn N; Bonney PL; Khanna C; Knapp DW
PLoS One; 2015; 10(9):e0136688. PubMed ID: 26352142
[TBL] [Abstract][Full Text] [Related]
5. Humoral and cellular immune reactions against tumor cells in patients with urinary bladder carcinoma. Correlation between direct and antibody-dependent cell-mediated cytotoxicity.
Hansson Y; Paulie S; Larsson A; Lundblad ML; Perlmann P; Näslund I
Cancer Immunol Immunother; 1983; 16(1):23-9. PubMed ID: 6556949
[TBL] [Abstract][Full Text] [Related]
6. CD204⁺ tumor-associated macrophages are associated with clinical outcome in canine pulmonary adenocarcinoma and transitional cell carcinoma.
Yokota S; Kaji K; Yonezawa T; Momoi Y; Maeda S
Vet J; 2023; 296-297():105992. PubMed ID: 37164121
[TBL] [Abstract][Full Text] [Related]
7. Lymphatic invasion is a significant indicator of poor patient outcome in canine bladder urothelial carcinoma.
Govoni VM; Pigoli C; Sueiro FAR; Zuliani F; da Silva TO; Quitzan JG; Laufer-Amorim R; Grieco V; Fonseca-Alves CE
Open Vet J; 2021; 11(4):535-543. PubMed ID: 35070848
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic and molecular characterization of novel pulmonary adenocarcinoma cell lines established from a dog.
Kobayashi K; Takemura RD; Miyamae J; Mitsui I; Murakami K; Kutara K; Saeki K; Kanda T; Okamura Y; Sugiyama A
Sci Rep; 2023 Oct; 13(1):16823. PubMed ID: 37798461
[TBL] [Abstract][Full Text] [Related]
9. Pan-tumour analysis of COX-2 expression in dogs.
Eto S; Shinada M; Saeki K; Tsuboi M; Kamoto S; Yoshitake R; Chambers J; Uchida K; Kato D; Nishimura R; Nakagawa T
Vet J; 2024 Apr; 304():106064. PubMed ID: 38242282
[TBL] [Abstract][Full Text] [Related]
10. Critical diagnostic and cancer stem cell markers in neoplastic cells from canine primary and xenografted pulmonary adenocarcinoma.
Tangchang W; Kim Y; Oh YI; Lee BW; Kim H; Yoon B
J Vet Sci; 2022 Nov; 23(6):e89. PubMed ID: 36448435
[TBL] [Abstract][Full Text] [Related]
11. [Clinically rare subtypes of prostate cancer: Progress in research].
Sheng ZC; Dong J; Xu S
Zhonghua Nan Ke Xue; 2023 Mar; 29(3):264-268. PubMed ID: 38597709
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive genomic characterization of five canine lymphoid tumor cell lines.
Roode SC; Rotroff D; Richards KL; Moore P; Motsinger-Reif A; Okamura Y; Mizuno T; Tsujimoto H; Suter SE; Breen M
BMC Vet Res; 2016 Sep; 12():207. PubMed ID: 27639374
[TBL] [Abstract][Full Text] [Related]
13. A Retrospective Clinico-Pathologic Study of 35 Dogs with Urethral Transitional Cell Carcinoma Undergoing Treatment.
Ghisoni G; Foglia A; Sabattini S; Agnoli C; Dondi F; Perfetti S; Marconato L
Animals (Basel); 2023 Jul; 13(14):. PubMed ID: 37508172
[TBL] [Abstract][Full Text] [Related]
14. Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines.
Zuiverloon TCM; de Jong FC; Costello JC; Theodorescu D
Bladder Cancer; 2018 Apr; 4(2):169-183. PubMed ID: 29732388
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of stable red, far-red (fR) and near infra-red (NIR) transfected canine prostate cancer cell lines.
Liu W; Sender S; Kong W; Beck J; Sekora A; Bornemann-Kolatzki K; Schuetz E; Junghanss C; Brenig B; Nolte I; Murua Escobar H
Cancer Cell Int; 2020; 20():139. PubMed ID: 32368185
[TBL] [Abstract][Full Text] [Related]
16. Prostatectomy as a treatment for canine prostate cancer: a literature review.
Stans J
Open Vet J; 2020 Oct; 10(3):317-322. PubMed ID: 33282703
[TBL] [Abstract][Full Text] [Related]
17. Characterizing the molecular and immune landscape of canine bladder cancer.
Cronise KE; Das S; Hernandez BG; Regan DP; Dailey DD; McGeachan RI; Lana SE; Page RL; Gustafson DL; Duval DL
Vet Comp Oncol; 2022 Mar; 20(1):69-81. PubMed ID: 34021685
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of epithelial and mesenchymal cell markers in canine urinary bladder transitional cell carcinoma.
Shinada M; Saeki K; Yoshitake R; Eto S; Tsuboi M; Chambers JK; Uchida K; Kato D; Yoshimoto S; Kamoto S; Ikeda N; Kinoshita R; Fujita N; Nishimura R; Nakagawa T
Vet J; 2020 Dec; 266():105571. PubMed ID: 33323173
[TBL] [Abstract][Full Text] [Related]
19. RNAseq expression patterns of canine invasive urothelial carcinoma reveal two distinct tumor clusters and shared regions of dysregulation with human bladder tumors.
Parker HG; Dhawan D; Harris AC; Ramos-Vara JA; Davis BW; Knapp DW; Ostrander EA
BMC Cancer; 2020 Mar; 20(1):251. PubMed ID: 32209086
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
